The MRI Features in Patients with Rheumatoid Arthritis Treated with Tocilizumab, in Clinical Remission or Low Disease Activity State

Bensaoud Nada*, Samira Rostom, Rachid Bahiri and Najia Hajjaj-Hassouni

Department of Rheumatology, El Ayachi Hospital, Salé, Faculty of Medicine and Pharmacy, Mohammed Vth University; URAC 30, Rabat, Morocco

*Corresponding author: Bensaoud Nada, Department of Rheumatology, El Ayachi Hospital, University hospital of Rabat-Sale, PO Box: 10000, Sale, Morocco, Tel: 00212-677928973; Fax: 00212-37845898; E-mail: nadabensaoud@yahoo.fr

Received date: February 24, 2015; Accepted date: October 26, 2015; Published date: October 30, 2015

Copyright: © 2015 Nada B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Subclinical inflammation and radiographic progression have been described in rheumatoid arthritis (RA) patients whose disease are in remission or are showing a low level of activity. The aim of this study was to evaluate in patients with rheumatoid arthritis RA in clinical remission or low disease activity (LDA) using composites scores, the synovitis and the bone oedema using MRI by OMERACT RAMRIS score (RAMRIS bone oedema and synovitis RAMRIS).

Methods: In this longitudinal study, were included patients with rheumatoid arthritis according to the American College of Rheumatology ACR 2010 criteria with inadequate response or intolerance to conventional synthetic DMARD, treated with Tocilizumab (TCZ). Sociodemographic characteristics, clinical and laboratory for the disease were collected at baseline (M0) and 06 months (M6) of treatment. Clinical remission was defined by a DAS 28 ESR<2.6, a CDAI<2.8, a SDAI<3.3 and by ACR EULAR criteria. All patients underwent MRI of the dominant hand and wrist. MRI features were evaluated according to the Outcome Measure Clinical Trial in Rheumatoid Arthritis Rheumatoid Arthritis MRI Scoring system (OMERACT RAMRIS synovitis and bone oedema).

Results: 22 patients with RA were included, 19 females (86.4%), with a mean of age 42 ± 13.7 years. The mean disease duration was 8 ± 5.2 years. The mean DAS 28 was 5.8 ± 0.94. Three patients were excluded from the study for serious side effects. At 06 months, the median SDAI was 18 (10-27).The median CDAI was 10 (5-20).The mean RAMRIS score was 2.23 ± 6.33 for bone oedema, 4.76 ± 4.02 for synovitis and 43.32 ± 30 for erosion. Using DAS28ESR as criteria of remission, it did not exist significant differences between the 3 groups of patients (remission/LDA/active disease) for the presence of synovitis on MRI (p=0.43). There was also no difference between the three groups for the presence of bone oedema (p=0.08). Moreover, defining remission by SDAI, CDAI or ACR EULAR criteria, the RAMRIS synovitis and bone oedema RAMRIS did not differ by the level of disease activity.

Conclusion: This study suggests that patient in clinical remission or LDA evaluated by composites scores showed inflammation (synovitis and bone oedema) on MRI. Thus clinical remission would be different from the imaging remission. MRI and ultrasound are currently one of the criteria for remission in RA, further studies are needed in particular to determine the threshold definition of remission on MRI.

Keywords: Rheumatoid arthritis; Remission; Low disease activity; Bone oedema; Synovitis; Magnetic resonance imaging

Background

Various definitions of remission in rheumatoid arthritis (RA) have been proposed [1]. Patients can fulfill clinical criteria for remission, yet still have evidence of synovitis detectable clinically and by ultrasound, and this is associated with structural damage. Stricter remission criteria may more accurately reflect true remission [2]. The aim of the present study was to assess the MRI features (RAMRIS synovitis and RAMRIS bone oedema) in patients with rheumatoid arthritis in clinical remission or low disease activity state based on the DAS28, SDAI, CDAI and ACR EULAR.

Methods

Patients

In this longitudinal study (24 weeks follow up in an open label) twenty two patients were included from the department of Rheumatology Rabat-Sale university hospital. Inclusion criteria were patients with rheumatoid arthritis according to the American college of rheumatology ACR 2009 criteria.

All patients have had inadequate response or intolerance of DMARDs with no prior biologics treatments. The exclusion criteria were the presence of allergy to any component of Tocilizumab or the presence of indication against MRI.

Sexually active premenopausal women were required to have a negative urine pregnancy test at entry and to use effective contraception during the study period. Three patients were excluded before 24 weeks because of serious side effects. All participants gave written informed consent before screening. The study was approved by
Tocilizumab therapy

Each patient received intravenous injections of tocilizumab monotherapy (8 mg/kg/every 4 weeks) for 24 weeks.

Clinical assessment

Clinical assessment was performed for each patient by a trained rheumatologist blinded to the imaging findings. Swollen and tender joint counts and global visual analogue scale were performed at baseline and 24 weeks. Disease activity was assessed by DAS28 (disease activity score), CDAI (clinical disease activity index), SDAI (simplified disease activity index) and functional disability was estimated by the Moroccan Arabic version of the HAQ.

Assessment questionnaire (HAQ)

Laboratory assessment: Serum markers of inflammation, C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were obtained as the same day as MRI [3].

Magnetic resonance imaging

Image acquisition: MRI of the dominant wrist and 2nd to 5th metacarpophalangeal (MCP) joints was carried out at baseline and 6 months, using a 0.3 Tesla artoscan system (ESAOTE Biomedica, Genova, Italy) a dedicated extremity MRI unit. Patients were comfortably seated in an adjustable scanning chair, with the dominant hand positioned in a wrist coil in the magnet in neutral position. The imaging protocol comprised a coronal and axial short tau inversion recovery (STIR) sequence followed by coronal and axial T1-weighted turbo spin echo 3D images obtained before and after intravenous injection of Gadolinium. The post contrast coronal and axial images were started 3 min after the injection of contrast agent. The imaging parameters for the STIR sequence were as follows: repetition time 500 ms, echo time 18 ms, matrix size 256 × 160, field of view (FOV) 200 mm, slice thickness 3 mm. For the T1 weighted spin echo 3D sequences, the imaging parameters were as follows: repetition time 500 ms, Echo time 18 ms, matrix size 256 × 192, field of view (FOV) 200 mm, slice thickness 1 mm.

Image evaluation: All the MRI were scored for bone oedema, synovitis and bone erosion as defined in the OMERACT MRI RA recommendations [4]. Synovitis is assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and metacarpocarpal joints) and in each MCP joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.

Bone erosions: Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately (as for erosions). The scale is 0-3 based on the proportion of bone with oedema, as follows-0: no oedema; 1: 1-33% of bone edematous; 2: 34%-66% of bone edematous; 3: 67%-100%. Sum scores of synovitis, erosion, and oedema can be calculated by summation of individual joint scores, as a total sum or separately in the evaluated wrist and second to fifth MCP joints, respectively. For synovitis, the possible range of sum scores of unilateral second to fifth MCP joints, wrist joint, and both are 0-12, 0-9, and 0-21, respectively. The corresponding values for bone erosion are 0-80, 0-150, and 0-230 and for bone edema 0-24, 0-45, and 0-69, respectively.

OMERACT RAMRIS was assessed by two rheumatologists with documented experience and high agreement (inter reader intra-class coefficient of correlation (ICC) at 0.82 (CI at 95%0.80-0.92), intra reader ICC at 0.86 (CI at 95%0.81-0.96). The assessors were blinded to clinical and laboratory findings.

Primary outcome

The assessment of synovitis and bone oedema using MRI by OMERACT RAMRIS score (RAMRIS bone oedema and synovitis RAMRIS) in patients with rheumatoid arthritis RA in clinical remission or low disease activity (LDA) defining remission by DAS28 ESR.

Secondary outcomes

The assessment of RAMRIS bone oedema and synovitis RAMRIS in patients with rheumatoid arthritis in clinical remission or low disease activity using the CDAI, SDAI and ACR EULAR criteria to determine the level of the disease activity.

Statistical analysis

The data were expressed as the mean ± SD (standard deviation), medians and inter-quartiles for continuous variables and as frequency (%) for categorical variables. Descriptive analyses were performed to investigate patient characteristics. The Mann Whitney U test and t test for independent groups were used for pairwise group comparisons. The wilcoxon matched pairs rank signed test and t test for paired groups were used to compare baseline values with data at 24 weeks. Correlations were calculated by spearman or Pearson test according to the distribution of variables. P-values <0.05 were considered significant. The statistical package for social sciences18 (SPSS18) software was used for all data management and analysis.

Results

Twenty two patients with RA were included in the study. Nineteen females (86.4%), with a mean of age 42 ± 13.7. The mean disease duration was 8 years ± 5.2 years. The mean DAS28 was 5.78 ± 0.87. The median CRP was 16 mg/L (6.7 to 36.3). The average SDAI was 90 ± 34 (Table 1).

Three patients were excluded before 24 weeks because of serious side effects (pulmonary embolism in one case, acute hepatitis in one case, and heart failure in one case). A significant response was seen in all clinical outcomes at 24 weeks (Table 2). At 06 months, the mean DAS 28 was 1.9 ± 1.4. The median SDAI was 18 (10-27) and the median CDAI was 10 (5-20). The mean RAMRIS score was 2.23 ± 6.33 for bone oedema, 4.76 ± 4.02 for synovitis and 43.32 ± 30 for erosion.

At 06 months, 85.7% of patients were in remission according DASVS 28. Nineteen percent of patients were in remission using CDAI score, and 10% using SDAI and ACR EULAR criteria (Figure 1).
Using DAS28ESR as criteria of remission, it did not exist significant differences between the 3 groups of patients (remission/LDA/active disease) for the presence of synovitis on MRI (p=0.67), and their severity (RAMRIS synovitis p=0.50). There was also no difference between the three groups for the presence of bone oedema (p=0.55), and their severity by RAMRIS bone oedema (p=0.55).

Moreover, defining remission by SDAI and CDAI, the RAMRIS synovitis and bone oedema RAMRIS did not differ by the level of disease activity (Table 3).

**Discussion**

The results of the present study suggests that there is no difference of MRI data (synovitis and oedema bone) between patients treated with Tocilizumab, in remission or LDA using composites scores and patients with disease activity state. Thus clinical remission would be different from the imaging remission.

Rheumatoid arthritis is a chronic inflammatory immune-mediated disease characterized by polyarticular synovitis that can lead to joint destruction with impairment of function and quality of life. With recent improvements in the treatment of rheumatoid arthritis, remission has become an achievable goal for a large proportion of RA patients, and remission is now a defined target in current RA guidelines. However, there is concern about whether current criteria reflect true remission characterized by the abrogation of synovitis and consequently, a lack of radiographic progression [5,6].

Different studies have shown that progression of radiographic joint damage may occur in clinical remission, regardless of the choice of remission definition. This may be explained by subclinical inflammation [7].

---

**Table 1:** Characteristics of population sample at baseline. 1: Average; 2: Number and Percentage; 3: Median. HAQ: Health Assessment Questionnaire; DAS 28: Disease Activity Score in 28 Joints; CRP: Protein-C Reactive; ESR: Erythrocyte Sedimentation Rate; CDAI: Clinical Disease Activity Index; SDAI: Simplex Disease Activity Index.

<table>
<thead>
<tr>
<th></th>
<th>M0</th>
<th>M6</th>
<th>p</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>N=22</td>
<td>N=19*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAS Pain (0-100)</td>
<td>54.5 ± 12.9</td>
<td>5 (0-10)</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>Swollen joint (0-28)</td>
<td>9.0 ± 4.2</td>
<td>0 (0-1)</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.06 ± 0.74</td>
<td>0.12 (0-0.43)</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>CDAI</td>
<td>71.3 ± 20.9</td>
<td>10 (5-20)</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>SDAI</td>
<td>90.10 ± 34.08</td>
<td>18 (10-27)</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>DAS28</td>
<td>5.8 ± 0.94</td>
<td>1.9 ± 1.4</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>36.7 ± 23.4</td>
<td>4 (2-17)</td>
<td>0.001</td>
<td>[1]</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>16 (6.7-36.3)</td>
<td>2 (2-4.5)</td>
<td>&lt;0.0001</td>
<td>[3]</td>
</tr>
<tr>
<td>Corticoïdes dose (mg/day)</td>
<td>7.5 (0-10)</td>
<td>5 (0-5)</td>
<td>0.005</td>
<td>[3]</td>
</tr>
<tr>
<td>RAMRIS erosion (0-230)</td>
<td>43.3 ± 29.8</td>
<td>45.5 ± 30.4</td>
<td>0.34</td>
<td>[1]</td>
</tr>
<tr>
<td>RAMRIS bone oedema(0-69)</td>
<td>0 (0-7.2)</td>
<td>0 (0-0.2)</td>
<td>0.04</td>
<td>[3]</td>
</tr>
<tr>
<td>RAMRIS synovitis (0-21)</td>
<td>12.9 ± 5.0</td>
<td>4.7 ± 4.0</td>
<td>&lt;0.0001</td>
<td>[1]</td>
</tr>
</tbody>
</table>

**Table 2:** Evolution of clinical and biological parameters at 06 months. *03 patients were excluded from the study for serious side effects. 1: Average; 2: Number and Percentage; 3: Median. HAQ: Health Assessment Questionnaire; DAS 28: Disease Activity Score in 28 Joints; CRP: Protein-C Reactive; ESR: Erythrocyte Sedimentation Rate; CDAI: Clinical Disease Activity Index; SDAI: Simplex Disease Activity Index; RAMRIS: Rheumatoid Arthritis MRI Score.
The initiative to treat rheumatoid arthritis to achieve remission has impacted clinical practice internationally [5]. The use of composite disease activity measures has been advocated to assess disease in preference to ‘clinical judgment’. There are several composite measures which correlate well, higher values having poor functional and radiologic outcomes, but there remains disagreement in classifying disease activity states. Disease activity score assessing 28-joint (DAS28) versions using erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have good correlation but not equivalence but it’s overestimated remission compared to all other criteria [10]. The American college of rheumatology (ACR) and the European league against rheumatism (EULAR) have defined remission as a simplified disease activity index (SDAI) value of ≤ 3.3 (index-based definition). The SDAI is statistically comparable to DAS28, but comparable DAS28 cutoff scores may need downward revision.

Aletaha et al. suggested that DAS28-ESR 2.4 more suitably reflected remission. Matsui et al. suggested that DAS28-CRP underestimated disease activity. Inoue et al. found DAS28-CRP 2.3 matched DAS28-ESR remission in Japanese patients [10]. The present study suggests that composite scores overestimate remission and patients retain subclinical inflammation found on MRI. Our results join the various studies that have proven the dissociation between clinical remission according different composite scores and remission in imaging either by ultrasound (Ramirez J et al. [11]) or MRI (Gandjbakhch F et al. [12]) or both (Foltz V et al. [13]).

The term remission is still ill-defined, and the various remission criteria allow different degrees of disease activity to be called remission. Nevertheless, remission as a reflection of no, or at the most, minimal disease activity ought to ensure maximal reversal, preferably normalization of functional impairment and minimal progression of joint destruction, ideally halt and even healing of joint destruction [14].

However, stringent criteria are needed to define remission status, as some criteria in current use allow for considerable residual disease activity [15,17]. In recent years, ultrasound and magnetic resonance imaging techniques have revealed that a significant percentage of patients classified as being in clinical remission exhibit different grades of synovitis, and a subgroup of these patients suffer flares and/or joint damage during follow-up [6].

Ultrasound and MRI can detect inflammation that predicts subsequent joint damage, even when clinical remission is present and can be used to assess persistent inflammation. Magnetic resonance imaging (MRI) provides a greater sensitivity than clinical examination and radiography for assessing disease activity [7,17]. The role of imaging in the detection of inflammation and subsequent prediction of outcome has been discussed previously. There is good evidence to support the disparity between clinical remission and evidence of ongoing inflammation seen with various imaging modalities. Power doppler activity has been found in 15%-62% of patients in clinical remission according to DAS 28, American college of rheumatology or simplified disease activity index remission criteria, MRI synovitis in 96% and bone oedema in 52%. In one study, 60% of patients in disease activity score remission had increased uptake on scintigraphy. The presence of ultrasound synovial hypertrophy, power doppler activity and MRI synovitis at baseline in clinical remission has been shown to be significantly associated with structural progression at 1 year, even in asymptomatic joints.
Baseline ultrasound inflammatory activity in clinical remission also seems predictive of future disease flare, with 20% of patients experiencing a flare within 12 months in the absence of baseline ultrasound power doppler activity, compared with 47% in patients with baseline power doppler activity (p<0.009). Although radiographic progression can still be seen in clinical remission, individuals with sustained clinical remission show fewer signs of structural progression compared with patients with clinically relapsing disease [18].

In summary, sustained remission is seen in a significant proportion of patients under routine clinical care. However, different remission criteria have different stringencies and the SDAI and CDAI criteria appear to be the most stringent ones currently validated, allowing for only minimal residual joint counts and thus reflecting a state of no active disease more closely than other scores [14].

In the present study, defining remission by DAS 28 or SDAI or CDAI or ACR EULAR criteria, the RAMRIS bone oedema, as well as RAMRIS synovitis did not differ by level of disease. Although MRI and ultrasound are currently one of the criteria for remission in RA, further studies are needed in particular to determine the threshold definition of remission on MRI and therapeutic threshold intervention.

Conclusion

This study suggests that patient in clinical remission or LDA evaluated by composites scores showed inflammation (synovitis and bone oedema) on MRI. Thus clinical remission would be different from the imaging remission. MRI and ultrasound are currently one of the criteria for remission in RA, further studies are needed in particular to determine the threshold definition of remission on MRI.

References